Cg Oncology Inc

NASDAQ: CGON
$28.50
-$1.52 (-5.1%)
Closing price May 10, 2024

CGON Chart and Intraday Price

CGON Company Data

Asset Type Stock
Exchange NASDAQ
Currency USD
Country USA
Sector TECHNOLOGY
Industry GENERAL
Address NONE
Fiscal Year End None
Latest Quarter None
Market Cap 0.00M USD
CG Oncology, Inc., originally Cold Genesys, Inc., is a pioneering firm in oncolytic immunotherapy, focusing on innovative treatments for bladder cancer. Based in Irvine, California since 2010, the company is dedicated to creating therapies that aim to preserve the bladder in patients with various stages of bladder cancer. Their portfolio includes treatments like BOND-003, CORE-001, and CORE-002, targeting high-risk and muscle invasive bladder cancer, alongside therapies for intermediate-risk patients. CG Oncology is at the forefront of combining their treatments with other cancer therapies to enhance patient outcomes.

CGON Articles

Insider Buying at These Biotechs Is Huge
As January wound to a close, beneficial owners, executives, and other insiders took advantage of public offerings of stock at these biotech companies.
Trey Thoelcke
Published: